Akers Biosciences, Inc. (LON:AKR)‘s stock had its “corporate” rating restated by equities research analysts at FinnCap in a research note issued to investors on Tuesday.

Akers Biosciences (LON:AKR) opened at 183.00 on Tuesday. The firm’s market cap is GBX 9.98 million. Akers Biosciences has a 12 month low of GBX 78.75 and a 12 month high of GBX 255.00. The firm’s 50 day moving average is GBX 226.04 and its 200-day moving average is GBX 206.80.

ILLEGAL ACTIVITY WARNING: “Akers Biosciences’ (AKR) Corporate Rating Reiterated at FinnCap” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The original version of this report can be accessed at http://www.dailypolitical.com/2016/11/29/akers-biosciences-akr-corporate-rating-reiterated-at-finncap.html.

About Akers Biosciences

Akers Biosciences, Inc develops, manufactures and supplies point-of-care screening and testing products designed to bring health-related information to the patient or clinician. The Company’s product offerings and pipeline products focus on delivering diagnostic assistance in a range of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious diseases detection, as well as for on and off-the-job alcohol safety initiatives.

Receive News & Ratings for Akers Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.